Joint marketing of CytoSorb® with B. Braun's
newest OMNI® blood purification platform will offer
greater access of this advanced treatment of deadly inflammation to
critically ill patients.
MELSUNGEN, Germany and
MONMOUTH JUNCTION, N.J.,
March 2, 2021 /PRNewswire/ -- B.
Braun Avitum AG, a leading manufacturer of medical devices and
pharmaceutical products and services and CytoSorbents Corporation
(NASDAQ: CTSO), a critical care immunotherapy leader
commercializing its CytoSorb® blood purification
technology to treat deadly inflammation, announce the launch of a
global co-marketing agreement to promote the use of
CytoSorb® with B. Braun's latest OMNI®
continuous blood purification platform and OMNIset® Plus
bloodline set (set version 3.0 or higher).
The CytoSorb® adsorber is used in critical care
for the extracorporeal removal of cytokines and inflammatory
mediators from the bloodstream and can be operated with the B.
Braun OMNI® acute dialysis machine. B. Braun will supply
the market with the OMNI® and
OMNIset® Plus while CytoSorbents and its network of
direct sales, strategic partners, and distributors will continue to
supply the market with CytoSorb®.
CytoSorb® is CE Mark certified and distributed in
67 countries worldwide.
Dr. Holger Seeberg, Member of the
Management Board of B. Braun Avitum commented, "We are excited to
announce this co-marketing agreement with CytoSorbents. Through
this collaboration, we want to provide physicians and medical
centers with one of the most promising ways to control deadly
inflammation with one of the most capable blood purification
platforms available in critical care today."
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "We are delighted to add B. Braun,
a trusted global organization and leading player in renal
replacement therapy and intensive care medicine, to the
CytoSorbents partner network. B. Braun's
OMNI® platform is an elegant and powerful machine,
providing physicians the flexibility to use
CytoSorb® to treat patients suffering from a wide
range of deadly conditions in the intensive care unit."
Mr. Chris Cramer, Vice President
of Business Development at CytoSorbents added, "We are very excited
to begin this new partnership with B. Braun, a world class
company. We believe there are many synergies to this
partnership and we plan to work closely with B. Braun's global
commercial organization to expand the combined use of
CytoSorb®, a leading treatment of cytokine storm, with
B. Braun's latest extracorporeal platform, the
OMNI® and OMNIset® Plus bloodline
set, to help patients around the world."
This global co-marketing agreement applies to the countries
where both products are registered (US market is specifically
excluded). Financial terms of this agreement have not been
disclosed.
About B. Braun
B. Braun is one of the world's leading manufacturers of medical
devices and pharmaceutical products and services. With 64,000
employees in 64 countries, B. Braun develops high quality product
systems and services for users around the world. In 2019, the Group
generated sales of €7.5 billion. Every service provided by B. Braun
incorporates its entire expertise and the company's deep
understanding of users' needs. In developing its products, product
systems and services, B. Braun acts like a sparring partner. A
companion who promotes developments through constructive dialog and
the motivation to improve things. With its constantly growing
portfolio of effective medical care solutions, B. Braun makes a
substantial contribution towards protecting and improving people's
health.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union
with distribution in 67 countries around the world, as an
extracorporeal cytokine adsorber designed to reduce the "cytokine
storm" or "cytokine release syndrome" that could otherwise cause
massive inflammation, organ failure and death in common critical
illnesses. These are conditions where the risk of death is
extremely high, yet no effective treatments exist.
CytoSorb® is also being used during and after cardiac
surgery to remove inflammatory mediators that can lead to
post-operative complications, including multiple organ failure.
CytoSorb® has been used in more than 121,000 human
treatments to date. CytoSorb® has received CE-Mark
label expansions for the removal of bilirubin (liver disease),
myoglobin (trauma) and both ticagrelor and rivaroxaban during
cardiothoracic surgery. CytoSorb® has also
received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory failure,
in defined circumstances. CytoSorb® has also been
granted FDA Breakthrough Designation for the removal of ticagrelor
in a cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and multiple applications pending, including
ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ™, K+ontrol™, DrugSorb™, ContrastSorb, and
others. For more information, please visit the Company's
websites at www.cytosorbents.com and www.cytosorb.com or follow us
on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 5, 2020, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Cytosorbents
Contact:
Amy Vogel
Investor
Relations
(732)
398-5394
avogel@cytosorbents.com
B. Braun SE
Corporate Communications
Contact:
Mechthild Claes
Tel. +49 5661 71-3385
presse@bbraun.com
|
Public Relations
Contact:
Eric Kim
Rubenstein Public
Relations
212-805-3055
ekim@rubensteinpr.com
|
Photo -
https://mma.prnewswire.com/media/1447289/B_Braun_OMNI.jpg
Photo -
https://mma.prnewswire.com/media/1447290/CytoSorb_Device.jpg
Logo -
https://mma.prnewswire.com/media/1447291/B_Braun_Avitum_AG.jpg
Logo -
https://mma.prnewswire.com/media/1096384/CytoSorbents_Working_To_Save_Lives_Logo.jpg